Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies.

By R. Orlowski, T. Stinchcombe, B. Mitchell, T. Shea, A. Baldwin, S. Stahl, J. Adams, D. Esseltine, P. Elliott, C. Pien and 8 more. Journal of Clinical Oncology, 2002

765 citations recorded by the source corpus.

Subfields: Molecular Biology

View Paper: https://www.semanticscholar.org/paper/c9631e618082ebb55221cf0e7832a1e9217cf713

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. A. Goy
2. Masakazu Toi
3. Chikashi Nakanishi

Citations in the corpus

• Bortezomib as the First Proteasome Inhibitor Anticancer Drug: Current Status and Future Perspectives (2011, background): “The data from these trials showed an acceptable level of toxicity coupled with significant clinical benefit toward hematological malignancies [11].”
• Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. (2007, background): “schedule that allows full recovery of proteasome activity between doses (18, 19).”
• Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. (2006, result): “These data are supported by similar results from phase I and II studies of single-agent bortezomib in relapsed MCL.(34-38,41)”
• Nuclear factor-κB inhibitors as sensitizers to anticancer drugs (2005, background): “and bortezomib was well tolerated in Phase I/II clinical trials in patients with multiple myelom”
• The proteasome: a suitable antineoplastic target (2004, neutral): “A tolerable and efficacious dose and schedule of bortezomib in myeloma was defined in Phase I and II studies ( Table 3”